Robert Croop Selected Research

rimegepant sulfate

1/2022	Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis.
1/2022	P-Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects.
1/2022	Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating Women.
10/2021	Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant.
1/2021	Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
1/2021	Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
11/2020	Pain Freedom at 2-8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant: A Response.
9/2020	Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
1/2020	Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy.
1/2020	Testing rimegepant for migraine-time to revise the trial design? - Authors' reply.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert Croop Research Topics

Disease

12	Migraine Disorders (Migraine) 01/2022 - 01/2019
4	Pain (Aches) 01/2022 - 01/2019
2	Alzheimer Disease (Alzheimer's Disease) 01/2013 - 03/2012
1	Body Weight (Weight, Body) 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Dizziness (Lightheadedness) 01/2022
1	Sleepiness 01/2022
1	Urinary Tract Infections (Urinary Tract Infection) 01/2019
1	Nausea 01/2019
1	Cognitive Dysfunction 01/2013
1	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 06/2009
1	Alcoholism (Alcohol Abuse) 12/2002

Drug/Important Bio-Agent (IBA)

12	rimegepant sulfateIBA 01/2022 - 01/2019
8	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 01/2022 - 01/2019
3	erenumabIBA 01/2021 - 01/2020
3	Calcitonin Gene-Related PeptideIBA 01/2021 - 01/2020
2	ubrogepantIBA 01/2022 - 11/2020
2	lasmiditanIBA 01/2022 - 11/2020
2	galcanezumabIBA 01/2021 - 09/2020
2	Monoclonal AntibodiesIBA 09/2020 - 01/2020
2	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)IBA 01/2020 - 11/2019
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2022
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2022
1	Quinidine (Chinidin)FDA LinkGeneric 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	LigandsIBA 09/2020
1	fremanezumabIBA 09/2020
1	TabletsIBA 01/2019
1	BMS 708163IBA 01/2013
1	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 03/2012
1	Amyloid (Amyloid Fibrils)IBA 03/2012
1	Adrenocorticotropic Hormone (ACTH)FDA Link 06/2009
1	EnzymesIBA 12/2002
1	Naltrexone (ReVia)FDA LinkGeneric 12/2002

Therapy/Procedure

3	Therapeutics 01/2021 - 01/2020